U.S. Scientists Warn That Trump’s Cuts Will Set Off a Brain Drain

Ardem Patapoutian’s life story represents far more than the traditional American dream — it encapsulates the unique promise of American scientific innovation. Born in Lebanon, he fled civil war and arrived in Los Angeles in 1986 at the age of 18. To make ends meet, he spent his first year in the U.S. writing for an Armenian newspaper and working nighttime shifts delivering pizzas for Domino’s. These efforts were part of a larger goal: to qualify for admission to the University of California, where he eventually completed his undergraduate studies and later earned a postdoctoral fellowship in neuroscience.

Through dedication and scientific brilliance, Patapoutian established his own research lab at Scripps Research Institute in San Diego with funding from the National Institutes of Health (NIH). His groundbreaking work led to the discovery of how humans perceive the sensation of touch — a finding that earned him the Nobel Prize in Physiology or Medicine in 2021.

Despite such extraordinary achievements, Patapoutian’s current research into pain treatment methods has come to a standstill. Federal funding for his work was frozen amid budget cuts under the Trump administration. In February, Patapoutian expressed his concern on Bluesky, warning that continued reductions in science funding would hinder biomedical research and likely push talented scientists to seek opportunities elsewhere. Not long after his post, he received an enticing offer from China: a blank check to relocate his lab to any city or university of his choosing, with guaranteed funding for two decades.

He declined. His deep loyalty to the United States — his adopted home — compelled him to stay. But many younger scientists at the beginning of their careers face far more uncertainty, and the allure of stability and funding abroad is becoming increasingly difficult to resist.

Experts now warn that the very foundation of America’s scientific leadership is in jeopardy. China and several European nations are actively investing in talent recruitment and research infrastructure. A recent analysis in Nature revealed a stark trend reversal: applications from China and Europe for graduate and postdoctoral positions in the U.S. have fallen dramatically since President Trump’s term began. Conversely, U.S.-based postdocs and grad students are applying in record numbers for international positions.

In France, a university that opened new positions specifically for scientists who lost federal grants in the U.S. had to close applications due to overwhelming interest. A research institute in Portugal reported a tenfold increase in inquiries from junior faculty members currently working in the United States.

“We’re conducting a massive and risky experiment with our scientific enterprise,” said Marcia McNutt, president of the National Academy of Sciences. “And China is essentially acting as the control group. They’re not slashing their science budgets — we are.”

Since the 1950s, U.S. government investment in research — via institutions like the NIH and the National Science Foundation (NSF) — has made the country a global leader in science and innovation. This model, advocated by Vannevar Bush in his historic report Science, The Endless Frontier, created a virtuous cycle: federal funding led to groundbreaking discoveries, which in turn boosted the country’s technology sector and reinforced America’s leadership.

Over the decades, this system attracted a steady stream of international scholars. Many of these foreign-born researchers came to the U.S. to work in elite university labs, often for modest compensation, simply for the opportunity to learn and collaborate with the best in the field. Many remained in the country, ultimately contributing to critical sectors such as defense, engineering, and biotechnology. Today, approximately half of all Ph.D. holders in the U.S. workforce in these fields were born outside the country.

But the future of this system is now under threat. Alongside budget cuts, new immigration policies have created an atmosphere of fear and uncertainty. Many international students and researchers have had their visas revoked, delayed, or canceled altogether. Even prestigious institutions like Harvard were targeted, with the administration seeking to eliminate funding for international students — a move temporarily blocked by the courts but seen as a warning shot.

Former Secretary of State Marco Rubio vowed to revoke visas of Chinese students in so-called “critical fields,” a category that includes many STEM disciplines. Ironically, in numerous U.S. labs, Chinese students and researchers significantly outnumber their American-born counterparts.

Despite President Trump’s stated desire to maintain scientific superiority over international competitors, his administration’s actions often contradicted that goal. In a letter to his science adviser, Michael Kratsios, Trump emphasized the need to rekindle the ambition that fueled past scientific breakthroughs. Yet Kratsios advocated for shifting the financial burden to philanthropists and private companies, arguing that federal funding often gets lost in bureaucracy.

But philanthropy has its limits. At Johns Hopkins University — the top recipient of NIH funding — even significant private donations, such as those from Michael Bloomberg, can’t fully replace federal support. Moreover, industry rarely funds basic research, and private sector research typically requires higher wages than academic settings can offer.

Patapoutian sees this instability as a strategic advantage — for China. “This isn’t just about international students,” he warned. “The whole ecosystem is frozen in uncertainty. You can’t plan long-term. When grants are suddenly frozen or cut, it throws the entire system into chaos.”

Nearly half of his lab members are international students or postdocs. But international interest is waning, and like many lab directors, Patapoutian isn’t hiring new researchers. The priority now is just keeping current staff employed.

In the early 20th century, American scientists often traveled to Europe for advanced research opportunities. That changed when fascism forced many Jewish scientists to flee Europe and find refuge — and new careers — in the United States. After World War II, the U.S. recruited foreign experts, including rocket scientists, which helped achieve milestones like the moon landing.

Now, a reversal is underway. For early-career scientists, countries outside the U.S. increasingly offer more reliable funding, secure positions, and supportive infrastructure. “They’re not just recruiting talent,” said McNutt, “they’re offering stability, funding, and resources without question.”

At Johns Hopkins, neuroscience department chair Richard Huganir expressed grave concern over the future. His department includes 36 labs with about 100 grad students and postdocs — around 30% of whom are international. “Losing them would be catastrophic,” he said. “They’re essential to the entire scientific fabric of this country.”

Many of these researchers are now returning home, to China, Korea, or elsewhere. Beyond the brain drain, Huganir fears increasing international isolation. He canceled plans to host a major international conference at Hopkins because foreign scientists were unwilling to travel to the U.S. Organizers discussed relocating it to Oxford in the UK, but then realized many international students in the U.S. would avoid attending, fearing they wouldn’t be able to reenter the U.S.

Meanwhile, Robert F. Kennedy Jr., now a federal health official, proposed a ban on NIH scientists publishing in leading journals — claiming they are “corrupt.”

Mathias Unberath, a German computer scientist at Hopkins, has 13 Ph.D. students and two postdocs — all but five are foreign-born. Now, even his top students are applying to jobs in Europe, spooked by the uncertain research climate in the U.S. One American student with multiple accolades took a postdoc offer in Germany.

Unberath himself faced challenges — while in the hospital with his wife for the birth of their child, the Trump administration suddenly suspended H-1B visas. He held one at the time. Now, even if students get visas, they’re discouraged by slashed NSF and NIH budgets and the uncertainty of securing early-career grants.

Daphne Koller, an Israeli-born computer scientist, earned her Ph.D. at Stanford, became a professor, won a MacArthur Fellowship, and founded two tech companies: Coursera and Insitro. She noted that most of her early employees were foreign-born, recruited directly from American universities.

“I’d love for the U.S. to cultivate more homegrown scientific talent,” she said, “but being a global magnet for the best minds has always been one of America’s greatest strengths.”

Perhaps no institution has felt the impact more than Harvard. The administration has singled it out in its broader battle against higher education, which it views as overly progressive.

Rudolf Pisa, a postdoc in cell biology, lost his NIH transition grant — a critical support for young scientists. He came to the U.S. from the Czech Republic for its bold scientific environment. Now, he and his American wife, a neuroscientist at Boston University, are planning a move to Europe.

“Just two months ago, I wouldn’t have even considered this,” he said. “I thought I was a good investment for this country.”

His supervisor, Tom Rapoport, has a personal history shaped by political interference in science. His parents, Jewish scientists, fled Nazi Germany, worked in the U.S., but were later blacklisted for Communist Party ties and moved to East Germany. After the Berlin Wall fell, Rapoport joined Harvard in 1995. Today, he’s facing his own lab’s decline: five students had their visas revoked before a judge intervened, and despite receiving a perfect peer-review score, he lost his NIH grant. His lab may shrink from 14 people to just 8 — only one of them American.

“I came here because American science represented excellence,” Rapoport said. “It was a scientific heaven. Or at least it used to be.”

He fears Americans may not realize what’s at stake. “People think we’re just takers,” he said, “but nearly every medicine people rely on today came from this system — the very one now being dismantled.”